Trial Profile
A prospective, first-in-human study investigated the safety, efficacy, pharmacokinetics and pharmacodynamics of AMG-333 in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Apr 2016
Price :
$35
*
At a glance
- Drugs AMG 333 (Primary)
- Indications Migraine
- Focus First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Amgen
- 25 Apr 2016 New trial record
- 12 Mar 2016 Population pharmacokinetics/pharmacodynamics and exposure-response analysis (n=40) were presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.